Related coverage linked through entity extraction aliases.
Mar 22, 2026
Prothena reported Q4 and full year 2025 financial results with $308.4 million in cash as partners Roche and Novo Nordisk initiated Phase 3 trials for prasinezumab and coramitug, both expected to complete in 2029.
Mar 21, 2026
AI-powered drugmaker Earendil Labs secured $787 million to advance biologics for autoimmune diseases and cancer, while Immunic locked in up to $400 million to fund Phase 3 trials of its multiple sclerosis therapy.
Mar 20, 2026
A Cleveland Clinic study of nearly 8,000 patients found minimal weight regain one year after stopping semaglutide or tirzepatide, contrasting with clinical trial results. Meanwhile, Eli Lilly's retatrutide and Roche's petrelintide continue development as next-generation obesity treatments.
Mar 19, 2026
Analysis shows around a third of 54 drugs on TrumpRx.gov are cheaper in the UK, while the platform offers significant savings primarily for obesity and fertility drugs not typically covered by insurance.
Mar 18, 2026
Proteolysis-targeting chimeras (PROTACs) are advancing from experimental to clinical-stage cancer therapies, with first candidates entering Phase III trials. The technology degrades target proteins rather than blocking them, offering new options for previously undruggable targets.
Mar 17, 2026
Roche deployed 2,176 new NVIDIA Blackwell GPUs, bringing its total above 3,500 chips across on-premise and cloud infrastructure. The expansion follows Eli Lilly's 1,016-GPU supercomputer launch and Recursion's 504-GPU system unveiled in 2024.
Mar 17, 2026
Global orphan drug sales are forecast to reach $409 billion by 2032, representing one-fifth of prescription drug sales, with Johnson & Johnson and Argenx leading the market amid regulatory uncertainty.
Mar 10, 2026
Roche's experimental breast cancer pill giredestrant combined with a CDK4/6 inhibitor failed to meet its primary endpoint in a Phase III trial for first-line treatment of ER-positive, HER2-negative advanced breast cancer, marking a setback for the drugmaker's next-generation hormone therapy program.
Mar 10, 2026
The FDA has accepted Roche's new drug application for giredestrant plus everolimus to treat ER-positive, HER2-negative, ESR1-mutated advanced breast cancer following prior endocrine therapy, with a decision expected by December 18, 2026.
Mar 09, 2026
Roche reported its Phase III MAJESTY study in primary membranous nephropathy met its primary endpoint with Gazyva/Gazyvaro, positioning the medicine as a potential first approved treatment for this rare kidney condition.
Mar 06, 2026
Zealand Pharma's petrelintide achieved up to 10.7% average weight loss after 42 weeks in a 493-patient phase 2 trial, with placebo-like tolerability but lower efficacy than competing amylin drugs, causing Zealand shares to drop 34%.
Mar 06, 2026
New research reveals how GLP-1 receptor agonists promote pancreatic health through gene expression changes and interact bidirectionally with gut microbiome, while real-world users report unexpected lifestyle changes alongside weight loss.
Mar 06, 2026
Genentech announced positive Phase II results for CT-388, a dual GLP-1/GIP receptor agonist, showing 22.5% placebo-adjusted weight loss at 48 weeks in people with obesity. The treatment was well-tolerated with low discontinuation rates.
Mar 06, 2026
Roche announced positive phase II results for obesity drug petrelintide showing 10.7% weight reduction, while the FDA set a December 18 decision date for breast cancer drug giredestrant.
Mar 06, 2026
Pfizer reported positive Phase 3 trial results for BRAFTOVI combination therapy in metastatic colorectal cancer and received FDA Priority Review for HYMPAVZI expansion to hemophilia patients including children.
Mar 05, 2026
Zealand Pharma reported full-year 2025 revenue of DKK 9.2 billion, bolstered by a significant upfront payment from Roche. The company ended the year with DKK 15.1 billion in cash and set 2026 operating expense guidance between DKK 2.72 billion and DKK 3.3 billion.
Mar 05, 2026
The cardiovascular biologics market is projected to reach $4.23 billion by 2033, while the cell therapy market is expected to reach $5.38 billion by 2032, driven by RNA-based therapies and regulatory approvals.
Mar 05, 2026
AbbVie has successfully transitioned from Humira dependence to growth driven by Skyrizi and Rinvoq, while maintaining a 54-year dividend increase streak and expanding its pipeline to roughly 90 programs through strategic acquisitions.
Mar 04, 2026
Roche signed an agreement to invest $478 million in Korea clinical trials over five years, marking the largest foreign pharmaceutical investment. Korean companies are also securing pre-approval licensing deals globally, demonstrating growing competitiveness.
Mar 02, 2026
The pharmaceutical industry is experiencing recovery driven by innovation in drug development, aggressive M&A activity, and expansion of drug development services. The sector faces both opportunities and headwinds including pipeline setbacks and regulatory pressures.
